Keywords
antiserum
recombinant
rEDIII
Zika virus
Abstract
Background: The recent global Zika virus (ZIKV) outbreak highlights the urgent development of ZIKV vaccines that offer rapid, precise and specific protection to those living in the high-risk regions. Despite many publications on in vitro development of ZIKV subunits as the vaccine candidates, due to the lack of knowledge on humoral and cellular immune responses against virus vaccines, a commercialized vaccine against Flavivirus in Philippines has been suspended due to a health scare in the public. Moreover, the close relationship between DENV and ZIKV has indicated serological cross-reactivity between both viruses. This has led to greater attentions to precautions needed during the design of ZIKV and DENV vaccines.
Materials and Methods: We pre-selected, synthesized and expressed the domain III of ZIKV envelope protein (namely rEDIII) based on a previously-established report (GenBank: AMC13911.1). The characteristics of purified ZIKV rEDIII was tested using SDS-PAGE, Western blotting and LC-MS/MS. Then, we assessed the possible outcome of pre-existing immunity against the rEDIII proteins by conducting dot-blotting assays using mice antisera pre-immunised with ZIKV particles (ZIKV strain: MRS_OPY_Martinique_PaRi_2015, GenBank: KU647676).
Results: We were able to express ZIKV rEDIII protein in bacterial system with valid protein conformation. Also, it was interesting that the pre-immunised hamster antiserum was able to recognise the rEDIII, which was sourced from a different ZIKV strain (GenBank: AMC13911.1). Conclusion: Despite its great antigenicity in eliciting humoral and cellular immunity against ZIKV infection, our finding calls for greater attention to evaluate the details of ZIKV rEDIII as a stand-alone vaccine candidate.
References
Tham HW, Balasubramaniam V, Ooi MK, Chew MF. Viral Determinants and Vector Competence of Zika Virus Transmission. Front Microbiol. 2018 May 23;9:1040.
Hussain A, Ali F, Latiwesh OB, Hussain S. A Comprehensive Review of the Manifestations and Pathogenesis of Zika Virus in Neonates and Adults. Cureus. 2018 Sep 12;10(9):e3290.
Theel ES, Hata DJ. Diagnostic Testing for Zika Virus: a Postoutbreak Update. J Clin Microbiol . 2018 Apr;56(4).
Barrett ADT. Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. NPJ Vaccines. 2018 Jun 11;3:24.
Watanabe S, Tan NWW, Chan KWK, Vasudevan SG. Dengue Virus and Zika Virus Serological Cross-reactivity and Their Impact on Pathogenesis in Mice. J Infect Dis. 2019 Jan 7;219(2):223–33.
Alshammari SA, Alamri YS, Rabhan FS, Alabdullah AA, Alsanie NA, Almarshad FA, et al. Overview of dengue and Zika virus similarity, what can we learn from the Saudi experience with dengue fever? Int J Sci . 2018 Jan;12(1):77-82.
Barbi L, Coelho AVC, de Alencar LCA, Crovella S. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis. Braz J Infect Dis. 2018 Mar - Apr;22(2):137-141.
Hills SL, Fischer M, Petersen LR. Epidemiology of Zika Virus Infection. J Infect Dis. 2017 Dec 16;216(suppl_10):S868-S874.
O’Dowd A. UK records four cases of Zika virus in past six weeks. BMJ. 2016 Feb 11;352:i875.
Taira M, Ogawa T, Nishijima H, Yamamoto K, Hotta C, Akita M, et al. The First Case of Zika Virus Isolated from a Japanese Patient Who Returned to Japan from Fiji in 2016. Jpn J Infect Dis. 2017 Sep 25;70(5):586–9.
Lamb LE, Bartolone SN, Tree MO, Conway MJ, Rossignol J, Smith CP, et al. Rapid Detection of Zika Virus in Urine Samples and Infected Mosquitos by Reverse TranscriptionLoop-Mediated Isothermal Amplification. Sci Rep. 2018 Feb 28;8(1):3803.
Shukla S, Hong S-Y, Chung SH, Kim M. Rapid Detection Strategies for the Global Threat of Zika Virus: Current State, New Hypotheses, and Limitations. Front Microbiol. 2016 Oct 24;7:1685.
Safronetz D, Sloan A, Stein DR, Mendoza E, Barairo N, Ranadheera C, et al. Evaluation of 5 Commercially Available Zika Virus Immunoassays. Emerg Infect Dis. 2017 Sep;23(9):1577–80.
Pawley D, Dikici E, Deo S, Daunert S. Current methods of Zika virus detection and limitations [Internet]. 2018. (Clinical laboratory International). Available from: https://www.clinlabint.com/fileadmin/user_upload/1._CLI_FebMarch_2018_FINAL.pdf
Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity,
and function of antibodies elicited by Zika virus infection. Science. 2016 Aug 19;353(6301):823–6.
Shanmugam RK, Ramasamy V, Shukla R, Arora U, Swaminathan S, Khanna N. Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation. Pathog Dis. 2019 Apr 1;77(3).
Liang H, Yang R, Liu Z, Li M, Liu H, Jin X. Recombinant Zika virus encelope protein elicited protective immunity against Zika virus in immunocompetent mice. PLoS One. 2018 Mar 28;13(3):e0194860.
Yang M, Sun H, Lai H, Hurtado J, Chen Q. Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice. Plant Biotechnol J. 2018 Feb;16(2):572–80.
Sylvia EA, Easther MK, Magdline SHS. Overexpression of recombinant domain III envelope protein of Zika virus. Malays J Microbiol. 2018;14(4):325–8.
Yang, Dent M, Lai H, Sun H, Chen Q. Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine. 2017 Jul 24;35(33):4287–94.
Yang M, Lai H, Sun H, Chen Q. Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci Rep. 2017 Aug 9;7(1):7679.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–5.
Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Biotechnology. 1992;24:145–9.
Ma B, Zhang K, Hendrie C, Liang C, Li M, Doherty-Kirby A, et al. PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003;17(20):2337–42.
Aylward B, Tangermann R. The global polio eradication initiative: lessons learned and prospects for success. Vaccine. 2011 Dec 30;29 Suppl 4:D80–5.
Parthasarathy A. Contamination of reconstituted multidose measles vaccine vial and toxic shock syndrome in Tamilnadu. Indian Pediatr. 2008 Jul;45(7):606.
Cousins S. Contaminated vaccine deaths a serious setback for Syria. Lancet. 2014 Sep 27;384(9949):1172.
Halstead SB. Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. Hum VaccinImmunother. 2018 May 14;14(9):2158–62.
Mahalingam S, Teixeira MM, Halstead SB. Zika enhancement: a reality check. Lancet Infect Dis. 2017 Jul;17(7):686-8
Martín-Acebes MA, Saiz J-C, Jiménez de Oya N. AntibodyDependent Enhancement and Zika: Real Threat or Phantom Menace? Front Cell Infect Microbiol. 2018 Feb 15;8:44.
Chiong FJK, Loewenthal M, Boyle M, Attia J. Serum sickness-like reaction after influenza vaccination. BMJ Case Rep [Internet]. 2015 Dec 16;2015. Available from: http://dx.doi.org/10.1136/bcr-2015-211917
Froehlich H, Verma R. Arthus reaction to recombinant hepatitis B virus vaccine. Clin Infect Dis. 2001 Sep 15;33(6):906–8.
de Alwis R, Williams KL, Schmid MA, Lai C-Y, Patel B, Smith SA, et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoSPathog. 2014 Oct;10(10):e1004386.
Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010 May 7;328(5979):745–8.
Zimmerman MG, Quicke KM, O’Neal JT, Arora N, Machiah D, Priyamvada L, et al. Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. Cell Host Microbe. 2018 Nov 14;24(5):731-42.e6.
Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus serocross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016 Sep;17(9):1102–8.
George J, Valiant WG, Mattapallil MJ, Walker M, Huang Y-JS, Vanlandingham DL, et al. Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques. Sci Rep. 2017 Sep 5;7(1):10498.
HogenEsch H, O’Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018 Oct 10;3:51.
Zidane N, Dussart P, Bremand L, Villani ME, Bedouelle H. Thermodynamic stability of domain III from the envelope protein of flaviviruses and its improvement by molecular design. Protein Eng Des Sel. 2013 Jun;26(6):389–99.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Asia Pacific Journal of Health Sciences and Research